Loading clinical trials...
Loading clinical trials...
A Real-world, Prospective, Multicenter Study to Assess the Safety and Effectiveness of Secukinumab (Cosentyx®) in Patients Aged 6 to Less Than 18 Years With Moderate to Severe Chronic Plaque Psoriasis in China
Conditions
Interventions
Cosentyx
Locations
7
China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Zhengzhou, Henan, China
Novartis Investigative Site
Shenyang, Liaoning, China
Novartis Investigative Site
Xian, Shanxi, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Start Date
September 8, 2022
Primary Completion Date
February 27, 2025
Completion Date
February 27, 2025
Last Updated
December 29, 2025
NCT06591273
NCT03598790
NCT03370133
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions